Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: Literature review

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 1, 2006, Pages 97-100

  Perrotta, Augustine L ^a,b  

^a Henry Ford Bi County Hospital   (United States)

^b NONE   (United States)

Author keywords

Chronic idiopathic immune thrombocytopenia (ITP); Influence of splenectomy and response to intravenous immunoglobulin (IVIg); Re treatment with rituximab

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RETREATMENT; REVIEW; SPLENECTOMY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SEX FACTORS; SPLENECTOMY;

EID: 32344453181     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200116     Document Type: Review

References (17)

1. Perrotta A, Abuel C. Response of chronic relapsing of ITP of 10 years duration to Rituximab. Blood 1998;92(10) (Suppl 1, (pt 2 of 2):88-b, Abstract 3360.
2. Perrotta AL, Abuel C. Update of response to Rituximab of chronic relapsing ITP. Blood 1999;94(10)(Suppl 1, pt 2 of 2):82b, Abstract 3528.
3. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98(4):952.
4. Aggarwal A, Catlett JP. Rituximab: An anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J 2002;95(10):1209.
5. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002;69(2):95.
6. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (Rituximab). Am J Hematol 2003;74(4):263.
7. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125(2):232.
8. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody Rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27(6)(Suppl 12):99.
9. Patel K, Berman J, Ferber A, et al. Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. Am J Hematol 2001;67(1):59.
10. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87(2): 189.
11. Delgado J, Bustos J, Jimenez-Yuse V, et al. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002;87(2): 215.
12. Stasi RA, Stipa E, Forte V, et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99(10):3872.
13. Zaja F, Vianelli N, Sperotto A, et al. The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88(5):538.
14. Riksen NP, Keuning JJ, Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura. Neth J Med 2003;61(7):262.
15. Thude H, Gruhn B, Werner U, et al. Treatment of a patient with chronic immune thrombocytopenic purpura with Rituximab and monitoring by flow cytometric analysis. Acta Haematol 2004;111(4):221.
16. Shanafelt TD, Madueme HL, Wolf RC, et al. Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evan's syndrome. Mayo Clinic Proc 2003;78(11):1340.
17. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clinic Proc 2004; 79(4):504.